AdvanCell
Changing the Course of Cancer Treatment
- Headquarters
- Sydney
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- advancell.com.au
- Total Funding
- $112.0M
- Last Round
- $112.0M Series CFeb 2025
About
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer using lead-212 (212Pb). Headquartered in Sydney, Australia with a growing US presence, the company operates a vertically integrated platform for manufacturing and delivering 212Pb-based therapies, with a lead program targeting PSMA for prostate cancer.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account